Conference Day One
Wednesday 18th October 2023
8:00 am Coffee & Registration
8:50 am Chair’s Opening Remarks
Bringing the Next Wave of Innate Immunotherapies to Market
9:00 am FIRESIDE DISCUSSION: Harnessing the Innate Immune Sytem to Bring Efficacious Immunotherapies to Patients in Need
Synopsis
- Where are we now and what are the most pressing challenges preventing innate immune therapies from getting to clinic?
- What are the big breakthroughs that we're seeing in this space?
- How do we address pipeline progression challenges?
- How is the investment landscape affecting Innate Killer Cell Therapy development?
- What does the future of this field need to achieve?
9:30 am PANEL DISCUSSION: Anticipating Key CMC Regulatory Challenges to Shorten Innate Cell Therapy Approval Pathways to Market
Synopsis
With the industry primed to enter the clinic with a variety of next generation innate cell therapies, attention turns to achieving a commercially viable drug product through CMC regulatory clarity to provide effective scale up.
Appreciating key CMC challenges for an effective and efficient scale up of innate cell therapies
Understanding the importance of engaging regulators as early as possible to defining specifications and acceptance criteria for a timely drug product release
- Elucidating karyotyping requirements for genetically engineered innate cell therapy products
- Revealing regulatory views on donor batch variability throughout the manufacturing process to achieve a successfully scaled allogenic innate cell therapy
10:00 am Morning Refreshment Break & Speed Networking
Utilising the Innate Immune System to Overcome Tumour Resistance Mechanisms & Facilitate a wider Immune Response
11:00 am ADAPT-NK –an allogeneic adaptive NK cell therapy platform to unleash NK cell potential
Synopsis
- Leveraging adaptive NK cell properties to circumvent inhibitory hurdles of NK cell therapies
- Utilizing highly cytotoxic ADAPT-NK cells against liquid and solid tumor targets, and in combination with engages
- Establishment of manufacturing protocol and cell banks to support dose-escalation and expansion of Phase I/II studies
11:30 am Case Study: Boosting NK Cells through Cytokine Conditioning: Promoting Ex Vivo Proliferative Capacity & Resistance to Immune Suppression in the TME
Synopsis
- Utilising cytokines to drive proliferative capacity of NK cells
- Leveraging stimulatory and inhibitory signalling to condition NK cells for increased cytotoxic capacity
- Overcoming immune suppression and shaping the TME through altered signalling and cytokine release
12:00 pm Case Study: Leveraging Dendritic Cell Biology to Improve NK-cell Based Therapeutic Approaches
Synopsis
- Dendritic cell biology can be used to improve NK-cell based therapeutic approaches
- Intratumoral allogeneic dendritic cells activate NK cells and broader antitumour immune responses
- Leukemic-derived dendritic cells can be used to expand memory NK cells for therapeutic purposes
12:30 pm Case Study: Clinical Gamma-Delta T-Cell Therapies, Demonstrating Persistence & Durability for Positive Outcomes in Hematological & Solid Tumours
Synopsis
- The first clinical data on gamma-delta T-cell therapies demonstrating persistence, durability and expansion in patients
- Leveraging gamma-delta T-cell properties to evade the endogenous immune response
- Intelligent engineering to maximise the tumor targeting ability of gamma-delta T-cells to bring cell therapies into solid tumours
1:00 pm Case Study: Allogeneic Invariant Natural Killer T-Cells: Approaches for Solid Tumor Treatment
Synopsis
- Why iNKT cells are a highly effective and efficient platform for allogeneic cell therapy
- Which approaches does MiNK Therapeutics pursue for the development of solid tumor therapy?
- Recent MiNK preclinical and clinical data on ongoing programs
1:30 pm Networking Lunch
Reconsidering Innate Cell Scarcity & Phenotypic Complexity to Promote an Effective & Efficient Engraftment Strategy
2:30 pm Session Reserved for Miltenyi Biotech
3:00 pm ROUNDTABLE DISCUSSION: Building Industry Synchronisation for a High- Quality Engraftment Strategy
Synopsis
With the innate cell therapy industry utilising iPSCs in addition to cord and peripherally-derived innate cells for therapeutic use, the need for engraftment synchronisation has never been more important for leaders in this dynamic space. This roundtable provides an opportunity for industry leaders to state their views on aspects of engraftment and discuss key topics such as patient conditioning and material characterisation to help understand ways to elevate a safe and effective engraftment strategy.
4:00 pm Innovator’s Poster Session
Evaluating the Role of Genetic Engineering to Reduce Immunogenicity & Increase Persistence of Innate Cell Therapies
5:00 pm Case Study: Harnessing Autologous NK Cells for Personalised Immunotherapy
Synopsis
- Engineering vs non-engineering strategies
- Important aspects of repeat dosing
- Strategies to increase cell potency, targeting and persistence
5:30 pm Case Study: Next Generation Engineering Platforms to Enhance Adoptive NK Cell Therapies
Synopsis
- Improving the specificity, persistence, and antitumour activity of NK cells by engineering them with CAR
- Precision genome editing of NK or CAR NK cells using CRISPR-cas9 technology to enhance their potency and circumvent tumour induced immunosuppression
- Arming NK cells or CAR NK cells with antibodies to improve their cytolytic activity and allow multi-targeting